Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the investigational drug catumaxomab is a
safe and effective treatment for recurrent symptomatic malignant ascites.